We are initiating coverage of Idogen, a Swedish early-stage biotech play focused on developing cell therapies. The concept could be used to treat patients by modifying their own immune system and has an attractive commercial potential. But it is still in the very early stages of development and many critical steps remain, hence, the risk level is high.